Intercept Pharmaceuticals, Inc. announced the appointment of M. Michelle Berrey, M.D., M.P.H., as President of Research & Development and Chief Medical Officer. Dr. Berrey was most recently President and Chief Executive Officer at Chimerix and previously served as Chief Medical Officer at Pharmasset from 2007 to 2012, prior to its acquisition by Gilead. While at Pharmasset, she played a critical role in the development of Sovaldi® (sofosbuvir), which established a transformational new treatment paradigm for patients with hepatitis C. Before joining Pharmasset, Dr. Berrey was Vice President, Viral Diseases, Clinical Pharmacology & Discovery Medicine at GlaxoSmithKline, where she was responsible for the early development of compounds for the treatment of HIV, hepatitis viruses and hepatic fibrosis. Dr. Berrey received her M.D. from the Medical College of Georgia and a Master of Public Health from Emory University.